
NexPoint Real Estate Finance heads into its third-quarter report with an odd disconnect. Last quarter management described a business that had turned a corner: a refinancing that removed its biggest balance sheet worry, apartment rents that finally stopped falling, and a struggling life science bet that was filling up. The market has not bought it. Shares have dropped about 10% since that report while the S&P 500 was flat, and they now sit at $15.30, just under the 200-day moving average and near the bottom of a post-earnings range that ran from $14.90 to $18.43. The November 5 release needs to show that the improvement is real rather than a good story told on one call.
The Street is braced for a weaker quarter. Consensus calls for earnings of $0.39 a share, down 22% from $0.50 a year ago, on revenue of $15.3 million, a 33% drop from the prior year and well below the $25.5 million reported last quarter. That revenue figure deserves caution, because this lender's top line can swing with fair value marks and loan payoffs, so a big drop does not by itself mean the core book is shrinking. Management guided to a midpoint of $0.43 for earnings available for distribution. Consensus sits below that, although the two numbers may not be measured the same way. More telling is cash available for distribution, which management treats as its main test of dividend coverage. The company guided that to a $0.55 midpoint, slightly above its prior quarter's guidance, after posting $0.58 for several straight quarters.
The most important check is whether the financing savings show up. The second-quarter Mizuho facility, combined with a total return swap, cut the net cost of the company's term borrowing to roughly 245 basis points over SOFR, about 130 basis points cheaper than the interim arrangement it replaced. This is the first full quarter with that structure in place. If the savings are real, CAD should land at or above guidance and keep the $0.50 dividend comfortably covered. A miss would suggest the savings are being eaten up somewhere else.
The operating story rests on two pieces of evidence. In residential, blended lease tradeouts moved from negative 1.7% in April to positive 0.3% in July. Management tied that to a sharp drop in new apartment supply, with 2026 deliveries expected to fall nearly by half. Further gains through the summer would back up that view and ease concern about the 2021 and 2022 vintage loans, which management named as the main remaining source of multifamily risk. In life science, the Alewife property was on track to reach 85% leased, and the sponsor was pursuing a refinancing or recapitalization that could return a large sum to NREF in the fourth quarter. Signs that the deal is on schedule, along with steady deployment into new 14% coupon preferred equity and mezzanine loans, would support the plan to redeploy that capital mostly into residential. Delays would weaken it.
The weak spot is book value, which fell from $19.10 to $18.60 over two quarters, mostly because of unrealized losses on the company's stock holdings. At today's price the shares trade at a steep discount to that figure, which signals that investors either doubt the marks or expect more losses. Sentiment is mildly bearish and essentially unchanged from last quarter, so expectations are low but not panicked.
The central question is whether cheaper financing and improving rents can lift cash earnings faster than mark-to-market losses wear down book value. If CAD holds near $0.55, book value stabilizes, and the Alewife recapitalization stays on schedule, the case for a turnaround remains intact. Another drop in book value would give skeptics more reason to keep the stock near the low end of its range.
This earnings preview was originally published on Earnings Whispers.
This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.
| Oct-28 | |
| Oct-27 | |
| Oct-06 | |
| Sep-30 | |
| Sep-16 | |
| Aug-06 | |
| Aug-06 | |
| Aug-06 | |
| Aug-05 | |
| Aug-04 | |
| Jul-28 | |
| Jul-09 | |
| Jun-17 | |
| Apr-30 | |
| Apr-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite